231 related articles for article (PubMed ID: 29125018)
1. The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder.
Ignjatović Ristić D; Cohen D; Obradović A; Nikić-Đuričić K; Drašković M; Hinić D
Nord J Psychiatry; 2018 Feb; 72(2):124-129. PubMed ID: 29125018
[TBL] [Abstract][Full Text] [Related]
2. Reliability of the Glasgow Antipsychotic Side-effects Scale for Clozapine Japanese version (GASS-C-J).
Kitagawa K; So R; Nomura N; Mizuno Y; Misawa F; Kodama M; Uchida H; Mimura M; Takeuchi H
PLoS One; 2020; 15(6):e0234864. PubMed ID: 32555706
[TBL] [Abstract][Full Text] [Related]
3. Glasgow Antipsychotic Side-effects Scale for Clozapine - Development and validation of a clozapine-specific side-effects scale.
Hynes C; Keating D; McWilliams S; Madigan K; Kinsella A; Maidment I; Feetam C; Drake RJ; Haddad PM; Gaughran F; Taylor M; Clarke M
Schizophr Res; 2015 Oct; 168(1-2):505-13. PubMed ID: 26276305
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Investigation of Clozapine Treatment in Autistic and Nonautistic Children and Adolescents in an Inpatient Clinic in Turkey.
Yalcin O; Kaymak G; Erdogan A; Tanidir C; Karacetin G; Kilicoglu AG; Mutlu C; Adaletli H; Gunes H; Bahali K; Ayik B; Uneri OS
J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):815-821. PubMed ID: 26771824
[TBL] [Abstract][Full Text] [Related]
5. [Validation of the Dutch Glasgow Anti- psychotic Side-Effect Scale for Clozapine].
Huisman R; Okhuijsen-Pfeifer C; Mulder EYH; Jongkind A; Cohen D; Bogers JPAM; van der Horst MZ; Luykx JJ
Tijdschr Psychiatr; 2021; 63(4):270-275. PubMed ID: 33913142
[TBL] [Abstract][Full Text] [Related]
6. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
Byerly MJ; Nakonezny PA; Rush AJ
Schizophr Res; 2008 Mar; 100(1-3):60-9. PubMed ID: 18255269
[TBL] [Abstract][Full Text] [Related]
7. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders.
de Haan L; Linszen DH; Gorsira R
J Clin Psychiatry; 1999 Jun; 60(6):364-5. PubMed ID: 10401913
[TBL] [Abstract][Full Text] [Related]
8. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates.
Lamberti JS; Costea GO; Olson D; Crilly JF; Maharaj K; Tu X; Groman A; Dietz MB; Bushey MP; Olivares T; Wiener K
J Clin Psychiatry; 2005 Jul; 66(7):900-6. PubMed ID: 16013906
[TBL] [Abstract][Full Text] [Related]
9. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].
Carpiniello B; Mellino G; Pintore S; Puddu L; Pinna F
Clin Ter; 2011; 162(4):331-41. PubMed ID: 21912821
[TBL] [Abstract][Full Text] [Related]
11. The European experience with use of clozapine.
Naber D; Hippius H
Hosp Community Psychiatry; 1990 Aug; 41(8):886-90. PubMed ID: 1976107
[TBL] [Abstract][Full Text] [Related]
12. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
Wheeler AJ
Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with subjective side-effects during clozapine treatment.
Seppälä N; Leinonen E; Viikki M; Solismaa A; Nuolivirta T; Kampman O
Nord J Psychiatry; 2015 Apr; 69(3):161-6. PubMed ID: 25225739
[TBL] [Abstract][Full Text] [Related]
14. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine.
Fuller MA; Borovicka MC; Jaskiw GE; Simon MR; Kwon K; Konicki PE
J Clin Psychiatry; 1996 Nov; 57(11):514-8. PubMed ID: 8968299
[TBL] [Abstract][Full Text] [Related]
15. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study.
Ciapparelli A; Dell'Osso L; Pini S; Chiavacci MC; Fenzi M; Cassano GB
J Clin Psychiatry; 2000 May; 61(5):329-34. PubMed ID: 10847306
[TBL] [Abstract][Full Text] [Related]
16. Clozapine: more side effects but still the best antipsychotic.
Kang X; Simpson GM
J Clin Psychiatry; 2010 Aug; 71(8):982-3. PubMed ID: 20797378
[No Abstract] [Full Text] [Related]
17. Switching to Clozapine Using Immediate Versus Gradual Antipsychotic Discontinuation: A Pilot, Double-Blind, Randomized Controlled Trial.
Takeuchi H; Lee J; Fervaha G; Foussias G; Agid O; Remington G
J Clin Psychiatry; 2017 Feb; 78(2):223-228. PubMed ID: 28234436
[TBL] [Abstract][Full Text] [Related]
18. Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.
Siskind DJ; Harris M; Phillipou A; Morgan VA; Waterreus A; Galletly C; Carr VJ; Harvey C; Castle D
Epidemiol Psychiatr Sci; 2017 Jun; 26(3):325-337. PubMed ID: 27426892
[TBL] [Abstract][Full Text] [Related]
19. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
[TBL] [Abstract][Full Text] [Related]
20. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia.
McElroy SL; Dessain EC; Pope HG; Cole JO; Keck PE; Frankenberg FR; Aizley HG; O'Brien S
J Clin Psychiatry; 1991 Oct; 52(10):411-4. PubMed ID: 1938976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
